middle.news
Eve Health Accelerates Fast-Acting Pharma with SAS-B Validation and Licensing Deals
8:22am on Thursday 26th of March, 2026 AEDT
•
Healthcare
Read Story
Eve Health Accelerates Fast-Acting Pharma with SAS-B Validation and Licensing Deals
8:22am on Thursday 26th of March, 2026 AEDT
Key Points
Two products launched under SAS-B regulatory pathway
Completed acquisition of Nextract IP for solubility enhancement
Capital-light, partner-led licensing and supply commercialisation model
Bioequivalence studies underway to support ARTG registration
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
EVE HEALTH (ASX:EVE)
OPEN ARTICLE